2025

Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L. and Spiliopoulou, P. (2025) Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance? International Journal of Molecular Sciences, (Accepted for Publication)

2024

Genta, S. et al. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9(11), 103978. (doi: 10.1016/j.esmoop.2024.103978) (PMID:39549683) (PMCID:PMC11615122)

Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)

Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)

Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)

Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)

Spiliopoulou, P. , Kaur, P., Hammett, T., Di Conza, G. and Lahn, M. (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resistance, 7, 2. (doi: 10.20517/cdr.2023.46) (PMID:38318526) (PMCID:PMC10838381)

Spiliopoulou, P. , Lopes, C. D. H. and Spreafico, A. (2024) Promising and minimally invasive biomarkers: targeting melanoma. Cells, 13(1), 19. (doi: 10.3390/cells13010019) (PMID:38201222) (PMCID:PMC10777980)

2023

Janse van Rensburg, H. J., Spiliopoulou, P. , Makhzoum, A. and Healy, B. D. (2023) Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery. Case Reports in Oncology, 16(1), pp. 662-669. (doi: 10.1159/000532004) (PMID:37933314) (PMCID:PMC10625819)

Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)

Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)

Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)

Spiliopoulou, P. , Vornicova, O., Genta, S. and Spreafico, A. (2023) Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. International Journal of Molecular Sciences, 24(2), 1294. (doi: 10.3390/ijms24021294) (PMID:36674809) (PMCID:PMC9862040)

2022

Janse van Rensburg, H. J., Spiliopoulou, P. and Siu, L. L. (2022) Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist, 27(5), pp. 352-362. (doi: 10.1093/oncolo/oyac047) (PMID:35285488) (PMCID:PMC9074993)

Spiliopoulou, P. , Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J. and Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43(5), pp. 379-390. (doi: 10.1016/j.it.2022.03.003) (PMID:35379580)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

2021

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

2020

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

2019

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

2018

Fleming, K., McGuinness, J., Kipgen, D., Glen, H. and Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, 6927639. (doi: 10.1155/2018/6927639) (PMID:30402314) (PMCID:PMC6192131)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

2017

Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

2016

Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Spiliopoulou, P. , Bowers, S. P., Gibson, S., White, J. and Reed, N. (2016) Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? Scottish Medical Journal, 61(2), pp. 111-116. (doi: 10.1177/0036933016635409) (PMID:27069005)

2015

Lemech, C., Dua, D., Newmark, J., Saggese, M., Simmons, E., Spiliopoulou, P. and Arkenau, H.-T. (2015) Patients' perceptions of research biopsies in Phase I Oncology Trials. Oncology, 88(2), pp. 95-102. (doi: 10.1159/000368161) (PMID:25322682)

Lindsay, C. R., Spiliopoulou, P. and Waterston, A. (2015) Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 7(2), pp. 107-121. (doi: 10.1177/1758834014566619) (PMID:25755683) (PMCID:PMC4346213)

2014

Spiliopoulou, P. and Arkenau, H.-T. (2014) Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 20(30), pp. 10288-10295. (doi: 10.3748/wjg.v20.i30.10288) (PMID:25132745) (PMCID:PMC4130836)

2011

Spiliopoulou, P. , Panwar, U. and Davidson, N. (2011) Rectal small cell carcinoma: A case report and review of the literature. Case Reports in Oncology, 4(3), pp. 475-480. (doi: 10.1159/000332760) (PMID:22114573) (PMCID:PMC3220900)

Articles

Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L. and Spiliopoulou, P. (2025) Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance? International Journal of Molecular Sciences, (Accepted for Publication)

Genta, S. et al. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9(11), 103978. (doi: 10.1016/j.esmoop.2024.103978) (PMID:39549683) (PMCID:PMC11615122)

Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)

Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)

Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)

Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)

Spiliopoulou, P. , Kaur, P., Hammett, T., Di Conza, G. and Lahn, M. (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resistance, 7, 2. (doi: 10.20517/cdr.2023.46) (PMID:38318526) (PMCID:PMC10838381)

Spiliopoulou, P. , Lopes, C. D. H. and Spreafico, A. (2024) Promising and minimally invasive biomarkers: targeting melanoma. Cells, 13(1), 19. (doi: 10.3390/cells13010019) (PMID:38201222) (PMCID:PMC10777980)

Janse van Rensburg, H. J., Spiliopoulou, P. , Makhzoum, A. and Healy, B. D. (2023) Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery. Case Reports in Oncology, 16(1), pp. 662-669. (doi: 10.1159/000532004) (PMID:37933314) (PMCID:PMC10625819)

Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)

Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)

Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)

Spiliopoulou, P. , Vornicova, O., Genta, S. and Spreafico, A. (2023) Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. International Journal of Molecular Sciences, 24(2), 1294. (doi: 10.3390/ijms24021294) (PMID:36674809) (PMCID:PMC9862040)

Janse van Rensburg, H. J., Spiliopoulou, P. and Siu, L. L. (2022) Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist, 27(5), pp. 352-362. (doi: 10.1093/oncolo/oyac047) (PMID:35285488) (PMCID:PMC9074993)

Spiliopoulou, P. , Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J. and Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43(5), pp. 379-390. (doi: 10.1016/j.it.2022.03.003) (PMID:35379580)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Fleming, K., McGuinness, J., Kipgen, D., Glen, H. and Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, 6927639. (doi: 10.1155/2018/6927639) (PMID:30402314) (PMCID:PMC6192131)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Spiliopoulou, P. , Bowers, S. P., Gibson, S., White, J. and Reed, N. (2016) Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? Scottish Medical Journal, 61(2), pp. 111-116. (doi: 10.1177/0036933016635409) (PMID:27069005)

Lemech, C., Dua, D., Newmark, J., Saggese, M., Simmons, E., Spiliopoulou, P. and Arkenau, H.-T. (2015) Patients' perceptions of research biopsies in Phase I Oncology Trials. Oncology, 88(2), pp. 95-102. (doi: 10.1159/000368161) (PMID:25322682)

Lindsay, C. R., Spiliopoulou, P. and Waterston, A. (2015) Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 7(2), pp. 107-121. (doi: 10.1177/1758834014566619) (PMID:25755683) (PMCID:PMC4346213)

Spiliopoulou, P. and Arkenau, H.-T. (2014) Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 20(30), pp. 10288-10295. (doi: 10.3748/wjg.v20.i30.10288) (PMID:25132745) (PMCID:PMC4130836)

Spiliopoulou, P. , Panwar, U. and Davidson, N. (2011) Rectal small cell carcinoma: A case report and review of the literature. Case Reports in Oncology, 4(3), pp. 475-480. (doi: 10.1159/000332760) (PMID:22114573) (PMCID:PMC3220900)